varicella vaccine + MMR + DTaP

This drug entry refers to the co-administration of Sinovac (Dalian) Vaccine Technology Co., Ltd.'s live attenuated varicella vaccine (branded as PROVARIX) with Measles, Mumps, and Rubella (MMR) and Diphtheria, Tetanus, and acellular Pertussis (DTaP) vaccines. It is currently being evaluated in a Phase IV clinical trial to assess the immunogenicity and safety of simultaneous or sequential administration in healthy children aged 18 to 24 months. PROVARIX is a live attenuated biologic vaccine targeting the varicella-zoster virus (VZV) to prevent chickenpox; it was launched in 2020 and received WHO prequalification in 2022. The study aims to confirm that the immune response to each component remains robust when these vaccines are given concurrently, a common practice in pediatric immunization schedules to reduce the number of clinical visits.

Brand names

PROVARIX

Other names

live attenuated varicella vaccine + MMR + DTaPvaricella vaccine + MMR + DTaP-Sinovac (Dalian) Vaccine Technology Co., Ltd.-chickenpox